Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 3 , Pages 371-373 , March 2006

Selecting an Antidepressant for the Treatment of Pediatric Depression

,Accepted 2 November 2005.

REFERENCES 

  1. Duffy A , Alda M , Kutcher S , et al.   A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment . J Clin Psychiatry . 2002;63:1171–1178
  2. Emslie GJ , Heiligenstein JH , Wagner KD , et al.   Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial . J Am Acad Child Adolesc Psychiatry . 2002;41:1205–1215
  3. Emslie GJ , Rush AJ , Weiberg WA , et al.   A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression . Arch Gen Psychiatry . 1997;54:1031–1037
  4. TADS Team  . The Treatment for Adolescents with Depression Study (TADS): short-term effectiveness and safety outcomes . JAMA . 2004;292:807–820
  5. Thase ME , Feighner JP , Lydiard RB . Citalopram treatment of fluoxetine nonresponders . J Clin Psychiatry . 2001;62:683–687
  6. Whittington CJ , Kendal lT , Fonagy P , Cottrel lD , Cotgrove A , Boddington E . Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data . Lancet . 2004;36:1341–1345

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.

 This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.

 Disclosure: Dr. Kratochvil has received grant support from, is a consultant to, and/or member of the speaker's bureau of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Bostic has received grant support and/or honoraria from Abbott, Forest, GlaxoSmithKline, Eli Lilly, and Pfizer. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)62029-3

doi: 10.1097/01.chi.0000197029.87378.1c

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 3 , Pages 371-373 , March 2006

Article Tools